psychotropic drugs in institutionalized patients with dementia have changed over the past decade. Although their use declined slightly over the study period, atypical antipsychotics continue to be used at a high rate. A decline in the use of benzodiazepines along with an increased use of sedative and non-sedative antidepressants suggests that the latter class of drugs is being substituted for the former in the management of neuropsychiatric symptoms. Psychotropic polypharmacy continues to be highly prevalent in these patient samples. (Am J Geriatr Psychiatry 2015; 23:1259e1269)
Key Words: Dispensing, antipsychotics, psychotropics, dementia, long-term care T wo out of three elderly long-term care residents suffer from dementia 1, 2 ; of these patients, approximately 80% 3 present with neuropsychiatric symptoms (NPS) such as anxiety, depression, agitation, psychological distress, psychosis, and/or insomnia. 4 Psychotropic medications are often used to manage such symptoms. 5 In the past decade, numerous drug regulatory agencies and clinical guidelines have cautioned against the use of antipsychotics, either conventional or atypical, to manage NPS; these warnings are based on findings of increased risks with these medications of cerebrovascular events and death.
6e12 Nonetheless, they continue to be prescribed and dispensed with varying rates around the world (from 7% to 40%). 13e19 The Canadian dementia guidelines have identified other classes of psychotropics that may be considered instead for the management of NPS; these include antidepressants (sedative and non-sedative), benzodiazepines, anti-epileptics and cognitive enhancers. 10 These guidelines, however, as well as those from other countries, highlight the variable evidence base for the use of these agents. 5, 20 It may be that each class of psychotropic is being differentially used to target specific NPS. Though not recommended, physicians may prescribe a combination of more than one psychotropic drug class in an attempt to manage the NPS, although the evidence base for this practice is even more limited. 21, 22 Although the dispensing rates of psychotropics in patients with dementia are well documented in the community setting, 23, 24 there are limited reports of their use in the long-term care setting. When compared with dementia patients in the community setting, long-term care patients are older, more frail, and at increased risk of the adverse effects of psychotropic medications; these include potentially dangerous drug interactions between co-dispensed psychotropic medications.
Physicians have become increasingly aware of the risks associated with the use of antipsychotics in the elderly and may be shifting their prescribing to other psychotropics, as single agents or in combination, to manage the NPS in older patients with dementia in long-term care facilities. We assessed the dispensing rate of antipsychotics and other classes of psychotropics in older adults with dementia living in longterm care facilities from 2004 to 2013.
METHODS
This study was approved by the Sunnybrook Health Sciences Centre research ethics board in Toronto, Ontario.
Study Design and Setting
We conducted a cross-sectional time-series analysis in Ontario, Canada. Ontario is the most populous province of Canada; at the beginning of 2004 approximately 1.3 million Ontarians were 65 years of age or older. By the end of 2017 this population is expected to grow to over 1.6 million. 25 
Data Source and Study Outcomes
We used data from a number of linked healthcare databases housed at the Institute of Clinical Evaluative Sciences, Ontario, Canada. These databases included the Registered Persons Database, which contains demographic information on all Ontario residents; the Ontario Health Insurance Plan database, which contains information on physician billing claims for inpatient procedures and outpatient physician visits; the Canadian Institutes of Health InformationeDischarge Abstract Database, which contains information about hospitalizations; and the Ontario Drug Benefits (ODB) database, which contains information on all medications dispensed for those aged 65 years or older, and identifies whether a patient resides in a long-term care facility. The ODB database has been found to have an error rate of less than 1%. 26 
Cohort Formation
For the purpose of this study, we divided each calendar year into four quarters (three-month periods; quarter 1 [Q1]: January to March, Q2: April to June, Q3: July to September, Q4: October to December). Data collection occurred from January 1, 2004, through March 31, 2013, generating a total of 37 quarters. For each quarter, the study sample comprised all residents of Ontario aged 66 years and above living in a long-term care home with a diagnosis of dementia. Patients were identified as having dementia if in the 5 years prior to the start of the interval they had a hospitalization involving a diagnosis of dementia (International Classification of Diseases, Tenth Revision [ICD-10] codes: F00, F01, F02, F03, F05.1, F06.5, F06.6, F06.8, F06.9, G30, G31, R54) or a physician-documented outpatient diagnosis for dementia (ICD-9 codes: 290, 331, 797). We selected a combination of both inpatient and outpatient codes to maximize the sensitivity of diagnoses; these codes have been used in previous large-scale database studies. 27e29 To determine long-term care residency status, we reviewed data from the most recently filled prescription in the one year prior to the start of each quarter. We did not include patients in their first year of prescription-drug coverage (65 years of age) to allow for a one-year look-back. Figure 1 outlines additional exclusion criteria and an example of how each cohort was developed.
Cohort Characteristics
Three quarters were selected a priori to examine patient characteristics at the beginning (January to March, 2004) , middle (January to March, 2009) and end (January to March 2013) of the study period. In addition to demographic characteristics, we used hospitalization records from the five years prior to the start of each quarter to characterize their dementia diagnosis and generate a Charlson comorbidity index 30 validated for administrative claims databases 31 (list of comorbidities presented in Table 1 ).
Prescription-Level Monitoring
For every quarter, we identified all prescriptions for the following psychotropic drug classes: atypical and conventional antipsychotics, non-sedative and sedative antidepressants, anti-epileptics, and benzodiazepines (specific drugs are listed in Appendix 1). We selected these medications as they are frequently dispensed for the management of the NPS of dementia. The rate of dispensing of each drug class was calculated quarterly by summing the number of patients dispensed a prescription for that drug class divided by the total number of patients in that quarter. Similarly, the rate of dispensing combination psychotropics was assessed by counting the number of patients who were dispensed with two or more unique psychotropic drug classes in the quarter being studied divided by the total number of patients in that quarter. Medications that did not have universal provincial coverage throughout the study period, or where the total count of prescriptions for the sample was less than 5, were excluded.
Statistical Analysis
To assess trends in the use of psychotropics, data was analyzed through time-series analysis 32 using exponential smoothing models. Time-series analyses are well-established methods that use a collection of techniques for modeling autocorrelations in temporally sequenced data. 32 Schwarz-Bayesian criteria were used to assess the best model fit. The level, trend, damping, and seasonality smoothing weights were determined to optimize the fit of the model. The statistical significance of the smoothing weights was tested using t tests. Stationarity was determined with the use of the autocorrelation function and the augmented Dickey-Fuller test. 33 The autocorrelation, partial autocorrelation, and inverse autocorrelation functions were further calculated for model parameter appropriateness and seasonality. The presence of white noise was assessed by examining the autocorrelations at various lag points using the Ljung-Box c 2 statistic. 34 Additionally, on a post hoc basis, we used exponential smoothing models to forecast the prescription rate of select psychotropic classes that exhibited impactful changes in dispensing during the 10-year study period (2004 to 2013); rates were forecasted to 2017. For assessment of differences in baseline characteristics across the selected time points, we conducted the c 2 test to examine the changes in proportion of categorical variables and Kruskal-Wallis test to examine the changes in medians of continuous variables. SAS software package for Windows, Version 9.3 (SAS Institute, Inc., Cary, NC,) was used for all statistical analyses.
RESULTS

Dementia Patients in Ontario Long-Term Care Homes
The number of patients included in the study increased by 21% from 49 (Table 1) .
Dispensing Changes
The proportion of patients dispensed each psychotropic drug class from January 1, 2004, to March 31, 2013, is presented in Figure 2 . Further statistical details of all model results presented herein are available in Table 2 . Among the classes of psychotropics included in the analyses, the proportion of patients on anti-epileptics (2 percentage point Number of pa ents on Jan 1 st 2004 who had demen a diagnosis within the previous 5 years.
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Pa ents with no ODB drug prescrip on in the previous 1 year to the beginning of each interval, n=5,419 59,785). Over the same period, the proportion of study patients on two or more different classes of psychotropics increased from 42% (21,019 of 49,251) to 50% (29,928 of 59,785) (Fig. 3) .
Projection of Dispensing Proportions
Based on the three psychotropic classes that exhibited the largest changes during the past decade (2004e2013), over the next four years (2014e2017) the following projections were made: The proportion of patients dispensed atypical antipsychotics may decrease from 34% to 31% and benzodiazepine use may decrease from 17% to 8% of patients while the proportion dispensed sedative antidepressant is expected to continue increasing from 32% to 36% of patients (Fig. 4) .
DISCUSSION
This study provides an analysis of trends over time (2004e2013) in the dispensing of six classes of psychotropics for the treatment of NPS among frail, older patients with dementia residing in long-term care facilities in Ontario, Canada. Over the past decade the overall psychotropic use has remained stable, with nearly three-quarters of all patients dispensed at least one medication. We observed a marginal but statistically significant decline in the proportion of patients dispensed antipsychotics (atypical and conventional) and anti-epileptics, and a more dramatic decline in proportion of patients on benzodiazepines was observed. Conversely, use of sedative and non-sedative antidepressants increased markedly. We also observed an overall increase in psychotropic combination therapy.
Interpretation
Among other findings, we saw a relatively high and steady usage of antipsychotics contrasting with a declining use of benzodiazepines; this pattern has been shown in previous studies. Those studies, however, did not examine psychotropic drug use in patients living in long-term care homes. 6, 19, 35, 36 The ongoing and projected high dispensing of atypical antipsychotics is of concern in the context of multiple warnings around cerebrovascular events and death associated with these agents. 6e12 On the other hand, the declining use of benzodiazepines is reassuring, as this would have likely resulted in fewer incidents of falls, fractures, and subsequent hospital admissions over the past decade. 37 This study highlights an increased use of nonsedative antidepressants. This trend needs to be viewed in the context of the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD), 12 which acknowledges that the use of antidepressants for managing affective disturbances associated with dementia are an option, but not a firm recommendation. These recommendations were partly based on a recent noneindustrysponsored large sample study, which failed to find any difference in the effects of sertraline, mirtazapine, or placebo in a randomized controlled setting. 38 Nevertheless, a more recent study focusing on the management of agitation in the context of dementia found some benefits with citalopram, a non-sedative antidepressant, 39 although there were adverse effects on cognition and the cardiovascular system. We also found that long-term care residents with dementia are increasingly being dispensed sedative antidepressants, which include medications such as trazodone, mirtazapine, and tricyclic antidepressants. We suspect that the increased use of sedative antidepressants is for the promotion of sedation, the treatment of comorbid depression, or to manage the agitation or aggression associated with dementia. Because of the large sample-based nature of this study we are unable to confirm any of the above reasons for this usage. Although not specifically tested, however, the converse increase in antidepressant dispensing with declines in benzodiazepine dispensing suggests that prescribers may be substituting benzodiazepines with antidepressants in an attempt to manage NPS. The ongoing and projected increase in the usage of sedative antidepressants is of possible concern as the safety and effectiveness of these agents is based only on smallscale studies.
40e42 For instance, the administration of mirtazapine for the treatment of depressive symptoms in outpatients with dementia led to reports of excessive drowsiness and sedation in 44% of patients. 24 Such symptoms could increase the risk of falls, injuries, fractures, and mortality. Therefore, the use of sedative antidepressants for the NPS of dementia needs to be further investigated.
One of the other recommendations of the CCCDTD was to reduce reliance on the usage of anti-epileptics, particularly valproate, as it has been associated with significant toxicity, accelerated brain volume loss, greater cognitive impairment, and a similar risk of mortality as that previously found with antipsychotics. 10 The ongoing use of such agents is therefore of some concern. We also examined the extent of the dispensing of combination psychotropic medications; such usage may further increase the risk of cognitive impairment, orthostatic hypotension, falls, and skeletal fractures. 43 In order to compare psychotropic prescription rates we divided the patients into two groups: those on one, and those on two or more classes of agents. We did not attempt to categorize whether certain psychotropic combination prescriptions were pharmacologically appropriate or not, as there is an inadequate evidence base for taking this approach. 44 We do, however, recognize that physicians caring for patients with dementia in long-term care settings are often faced with the dilemma of balancing the use of psychotropic combination therapy with its associated risks. These physicians must also take into account the need to reduce the anxiety in staff and other residents caused by patients' calling out, agitation, hallucinations, and other NPS associated with dementia. 45 Fortunately, it is possible to reduce potentially inappropriate combination therapy through concerted multidisciplinary and frequent medication reviews. 46 In light of the limitations posed by pharmacological treatments, nonpharmacological interventions using music or environmental manipulation may provide alternatives for the management of NPS. There is some evidence that such interventions can be of benefit if tailored to the individual patient, and if healthcare providers are given adequate support to offer such treatments. 47 High-quality large-scale studies for assessing the efficacy of such therapies have yet to be performed. 48 
Study Limitations
There are several limitations to the present study. First, this study was retrospective in nature and hence suffers from inherent biases associated with such a design. Second, healthcare databases do not code dementias using the more stringent standardized diagnostic criteria for characterizing the type or severity of dementia as suggested by the National Institute on Aging/Alzheimer's Association Diagnostic Guidelines for Alzheimer's Disease; such diagnoses are typically used for characterizing patients in prospective randomized controlled trials. Our approach of using either an outpatient, or an inpatient physician coding, however, would offer increased sensitivity, without compromising on specificity of diagnosis.
27e29 Third, we were unable to accurately capture the dispensing of cognitive enhancers as they were not universally covered under the drug compensation plan in Ontario (ODB) during the study period. Fourth, we did not characterize the usage of individual psychotropic within each drug class, as this would have led to an inordinately large amount of data, making it difficult to interpret the results. Fifth, additional clinical information is required to better characterize patients; this better understanding of a patient's needs will help to identify appropriate drug use, and to develop a structured approach for dealing with polymedicated patients. Finally, the extrapolated prediction-modeleprojected psychotropic usages are based on assumptions inherent to the model used, and as such do not account for outside variables that may influence future trends such as changes in formulary coverage, introduction of new medications, or changes in practice guidelines.
Conclusions and Implications
This study outlines current trends in the dispensing of various classes of psychotropics for the treatment of NPS in patients with dementia residing in long-term care facilities in Ontario, Canada. The results suggest a high prevalence of sedative antidepressant usage with a concomitant decline in the usage of antipsychotics and benzodiazepines, suggesting that the former have supplanted the latter in their role as sedative agents. The increase in psychotropic polypharmacy suggests an ongoing reliance on psychotropic usage in the management of patients with dementia in long-term care where provisions of nonpharmacological therapies are likely inadequate. In the absence of firm evidence from large-scale randomized controlled trials regarding the efficacy and safety of various psychotropics (including sedative antidepressants) for the treatment of NPS in the context of frail elderly with dementia in long-term care, this report represents an important contribution to research on a major public health concern. 
